Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10. září 2016 aktualizováno: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

991

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Bosna a Hercegovina
      • Banja Luka, Bosna a Hercegovina, 78000
      • Sarajewo, Bosna a Hercegovina, 71000
  • Brazílie
      • Belo Horizonte, Brazílie, 30150-281
      • Curitiba, Brazílie, 80530-010
      • Goiania, Brazílie, 74605-070
      • Itajai, Brazílie, 88301-220
      • JAU, Brazílie, 17210-080
      • Joao Pessoa, Brazílie, 58040280
      • Porto Alegre, Brazílie, 90610-000
      • Porto Alegre, Brazílie, 91350-200
      • Porto Alegre, Brazílie, 90430-090
      • Porto Alegre - Rs, Brazílie, 90050-170
      • Rio de Janeiro, Brazílie, 20560-120
      • Rio de Janeiro, Brazílie, 22260-020
      • Santo Andre, Brazílie, 09060-870
      • Sao Paulo, Brazílie, 1323020
      • Sao Paulo, Brazílie, 01317-000
  • Bulharsko
      • Plovdiv, Bulharsko, 4000
      • Sofia, Bulharsko, 1756
      • Sofia, Bulharsko, 1784
      • Varna, Bulharsko, 9002
  • Dánsko
      • Herlev, Dánsko, 2730
      • København, Dánsko, 2100
      • Odense, Dánsko, 5000
  • Filipíny
      • Diliman, Quezon City, Filipíny, 1100
      • Quezon City, Luzon, Filipíny, 1101
  • Finsko
      • Helsinki, Finsko, 00180
      • Tampere, Finsko, 33520
      • Turku, Finsko, 20520
  • Francie
      • Avignon, Francie, 84082
      • Bordeaux, Francie, 33076
      • Brest, Francie, 29609
      • Caen, Francie, 14076
      • Dijon, Francie, 21079
      • La Roche Sur Yon, Francie, 85925
      • Montpellier, Francie, 34298
      • Paris, Francie, 75248
      • Saint Brieuc, Francie, 22015
      • Saint Herblain, Francie, 44805
      • Vandoeuvre-les-nancy, Francie, 54511
  • Hongkong
      • Hong Kong, Hongkong
  • Indie
      • Bangalore, Indie, 560027
      • Gurgaon, Indie, 122001
      • Kolkata, Indie, 700 053
      • New Delhi, Indie, 110029
      • Pune, Indie, 411004
  • Itálie
      • Aviano, Itálie, 33081
      • Bologna, Itálie, 40138
      • Candiolo, Itálie, 10060
      • Genova, Itálie, 16132
      • Meldola, Itálie, 47014
      • Milano, Itálie, 20133
      • Milano, Itálie, 20141
      • Napoli, Itálie, 80131
      • Negrar, Itálie, 37024
      • Pisa, Itálie, 56100
      • Reggio Emilia, Itálie, 42100
      • Roma, Itálie, 00168
      • Rozzano, Itálie, 20089
      • Sassari, Itálie, 07100
      • Terni, Itálie, 05100
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
      • Edmonton, Alberta, Kanada, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 5L3
      • Vancouver, British Columbia, Kanada, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
      • Sudbury, Ontario, Kanada, J9P 3Y1
      • Toronto, Ontario, Kanada, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Kanada, J4V 2H1
      • Montreal, Quebec, Kanada, H1T 2M4
      • Montreal, Quebec, Kanada, H3T 1E2
      • Montreal, Quebec, Kanada, H2W 1T8
  • Kolumbie
      • Bogota, Kolumbie
      • Bogota, Kolumbie, 49 00
      • Monteria, Kolumbie
  • Korejská republika
      • Kyunggi-do, Korejská republika, 411-769
      • Seoul, Korejská republika, 110-744
      • Seoul, Korejská republika, 120-752
      • Seoul, Korejská republika, 135-710
  • Mexiko
      • Acapulco, Mexiko, 39670
      • Oaxaca, Mexiko, 68000
      • Toluca, Mexiko, 50180
  • Nový Zéland
      • Newtown, Nový Zéland, 6021
      • Palmerston North, Nový Zéland, 4442
  • Německo
      • Aschaffenburg, Německo, 63739
      • Berlin, Německo, 10367
      • Berlin, Německo, 13125
      • Berlin, Německo, 4169
      • Bonn, Německo, 53113
      • Dortmund, Německo, 44137
      • Freiburg, Německo, 79106
      • Fuerstenwalde, Německo, 15517
      • Hamburg, Německo, 20357
      • Karlsruhe, Německo, 76135
      • Kiel, Německo, 24105
      • Offenbach, Německo, 63069
      • Stralsund, Německo, 18435
  • Polsko
      • Bialystok, Polsko, 15-027
      • Gdansk, Polsko, 80-952
      • Krakow, Polsko, 31-531
      • Lublin, Polsko, 20-090
      • Opole, Polsko, 45-060
      • Poznan, Polsko, 61-866
      • Warszawa, Polsko, 02-781
  • Portugalsko
      • Coimbra, Portugalsko, 3000-075
      • Lisboa, Portugalsko, 1649-035
      • Porto, Portugalsko, 4200-072
  • Ruská Federace
      • Kemerovo, Ruská Federace, 650036
      • Moscow, Ruská Federace, 121356
      • St Petersburg, Ruská Federace, 197758
  • Singapur
      • Singapore, Singapur, 119074
      • Singapore, Singapur, 169610
  • Slovinsko
      • Ljubljana, Slovinsko, 1000
  • Spojené království
      • Bournemouth, Spojené království, BH7 7DW
      • Cardiff, Spojené království, CF14 2TL
      • Denbigh, Spojené království, LL18 5UJ
      • London, Spojené království, SE1 7EH
      • London, Spojené království, SW3 6JJ
      • Manchester, Spojené království, M20 4BX
      • New Castle Upon Tyne, Spojené království, NE7 7DN
      • Northwood, Spojené království, HA6 2RN
      • Poole, Spojené království, BH15 2JB
      • Preston, Spojené království, PR2 9HT
      • Romford, Spojené království, RM7 0AG
      • Sutton, Spojené království, SM2 5PT
      • Weston Super Mare, Spojené království, BS23 4TQ
  • Spojené státy
    • Arizona
      • Chandler, Arizona, Spojené státy, 85224
      • Tucson, Arizona, Spojené státy, 85719
    • California
      • Anaheim, California, Spojené státy, 92801
      • Anaheim, California, Spojené státy, 92807
      • Bakersfield, California, Spojené státy, 93309
      • Baldwin Park, California, Spojené státy, 91706
      • Bellflower, California, Spojené státy, 90706
      • Duarte, California, Spojené státy, 91010
      • Fontana, California, Spojené státy, 92335
      • Hayward, California, Spojené státy, 94545
      • Irvine, California, Spojené státy, 92618
      • La Jolla, California, Spojené státy, 92093
      • La Mesa, California, Spojené státy, 91942
      • Loma Linda, California, Spojené státy, 92354
      • Long Beach, California, Spojené státy, 90806
      • Los Angeles, California, Spojené státy, 90025
      • Los Angeles, California, Spojené státy, 90057
      • Los Angeles, California, Spojené státy, 90095-1772
      • Los Angeles, California, Spojené státy, 90034
      • Montebello, California, Spojené státy, 90640
      • Newport Beach, California, Spojené státy, 92660
      • Oakland, California, Spojené státy, 94611
      • Panorama City, California, Spojené státy, 91402
      • Riverside, California, Spojené státy, 92505
      • Roseville, California, Spojené státy, 95661
      • Sacramento, California, Spojené státy, 95825
      • San Diego, California, Spojené státy, 92123
      • San Diego, California, Spojené státy, 92120
      • San Francisco, California, Spojené státy, 94115
      • San Jose, California, Spojené státy, 95119
      • Santa Clara, California, Spojené státy, 95051
      • Santa Maria, California, Spojené státy, 93454
      • Santa Monica, California, Spojené státy, 90404
      • South San Francisco, California, Spojené státy, 94080
      • Thousand Oaks, California, Spojené státy, 91360
      • Vallejo, California, Spojené státy, 94589
      • Walnut Creek, California, Spojené státy, 94596
      • Woodland Hills, California, Spojené státy, 91367
    • Colorado
      • Fort Collins, Colorado, Spojené státy, 80528
    • Connecticut
      • Norwalk, Connecticut, Spojené státy, 06856
      • Norwich, Connecticut, Spojené státy, 06360
      • Stamford, Connecticut, Spojené státy, 06902
    • District of Columbia
      • Washington, District of Columbia, Spojené státy, 20010
    • Florida
      • Boca Raton, Florida, Spojené státy, 33486
      • Fernandina Beach, Florida, Spojené státy, 32034
      • Fort Myers, Florida, Spojené státy, 33916
      • Ft. Lauderdale, Florida, Spojené státy, 33316
      • Hollywood, Florida, Spojené státy, 33021
      • Jacksonville, Florida, Spojené státy, 32205
      • Jacksonville, Florida, Spojené státy, 32256
      • Jacksonville, Florida, Spojené státy, 32207
      • Jacksonville, Florida, Spojené státy, 32258
      • Kissimmee, Florida, Spojené státy, 34741
      • Lakeland, Florida, Spojené státy, 33804-1057
      • Miami, Florida, Spojené státy, 33136
      • Miami, Florida, Spojené státy, 33176
      • Miami, Florida, Spojené státy, 33133
      • Orange Park, Florida, Spojené státy, 32073
      • Pembroke Pines, Florida, Spojené státy, 33028
    • Georgia
      • Athens, Georgia, Spojené státy, 30607
      • Atlanta, Georgia, Spojené státy, 30342
      • Atlanta, Georgia, Spojené státy, 30322
      • Atlanta, Georgia, Spojené státy, 30341
      • Atlanta, Georgia, Spojené státy, 30318
      • Carrolton, Georgia, Spojené státy, 30117
      • Cartersville, Georgia, Spojené státy, 30121
      • Decatur, Georgia, Spojené státy, 30033
      • Douglasville, Georgia, Spojené státy, 30134
      • Macon, Georgia, Spojené státy, 31217
      • Marietta, Georgia, Spojené státy, 30060
    • Idaho
      • Boise, Idaho, Spojené státy, 83712
      • Meridian, Idaho, Spojené státy, 83642
      • Nampa, Idaho, Spojené státy, 83686
      • Post Falls, Idaho, Spojené státy, 83854
      • Twin Falls, Idaho, Spojené státy, 83301
    • Illinois
      • Chicago, Illinois, Spojené státy, 60612
      • Decatur, Illinois, Spojené státy, 62526
      • Effingham, Illinois, Spojené státy, 62526
      • Joliet, Illinois, Spojené státy, 60435
      • Morris, Illinois, Spojené státy, 60450
      • Peoria, Illinois, Spojené státy, 61615-7828
      • Skokie, Illinois, Spojené státy, 60076
      • Zion, Illinois, Spojené státy, 60099
    • Iowa
      • Bettendorf, Iowa, Spojené státy, 52722
    • Kansas
      • Wichita, Kansas, Spojené státy, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Spojené státy, 42001
    • Louisiana
      • Covington, Louisiana, Spojené státy, 70433
      • Lafayette, Louisiana, Spojené státy, 70503
      • Marrero, Louisiana, Spojené státy, 70072
      • Metairie, Louisiana, Spojené státy, 70006
      • New Orleans, Louisiana, Spojené státy, 70115
    • Maine
      • Kittery, Maine, Spojené státy, 03904
      • Wells, Maine, Spojené státy, 04090
      • York, Maine, Spojené státy, 03909
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21202
      • Baltimore, Maryland, Spojené státy, 21237
      • Bethesda, Maryland, Spojené státy, 20817
      • Rockville, Maryland, Spojené státy, 20850
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02215
      • Boston, Massachusetts, Spojené státy, 02114
      • Boston, Massachusetts, Spojené státy, 02118
      • Boston, Massachusetts, Spojené státy, 02115
      • Burlington, Massachusetts, Spojené státy, 01805
      • Peabody, Massachusetts, Spojené státy, 01960
    • Michigan
      • Brownstown, Michigan, Spojené státy, 48183
      • Dearborn, Michigan, Spojené státy, 48126
      • Detroit, Michigan, Spojené státy, 48201
      • Detroit, Michigan, Spojené státy, 48202
      • Saint Joseph, Michigan, Spojené státy, 49085
      • West Bloomfield, Michigan, Spojené státy, 48322
    • Minnesota
      • Edina, Minnesota, Spojené státy, 55414
      • Maplewood, Minnesota, Spojené státy, 55109
      • Minneapolis, Minnesota, Spojené státy, 55454
      • Saint Louis Park, Minnesota, Spojené státy, 55426
      • Saint Paul, Minnesota, Spojené státy, 55101
      • St. Louis Park, Minnesota, Spojené státy, 55426
    • Missouri
      • Joplin, Missouri, Spojené státy, 64804
      • Kansas City, Missouri, Spojené státy, 64111
      • Saint Louis, Missouri, Spojené státy, 63110
      • Saint Peters, Missouri, Spojené státy, 63110
      • St. Louis, Missouri, Spojené státy, 63141
      • St. Peters, Missouri, Spojené státy, 63376
    • Montana
      • Missoula, Montana, Spojené státy, 59802
    • Nebraska
      • Omaha, Nebraska, Spojené státy, 68114
    • Nevada
      • Henderson, Nevada, Spojené státy, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Spojené státy, 08002
      • Hackensack, New Jersey, Spojené státy, 07601
      • Morristown, New Jersey, Spojené státy, 07962
      • Parsippany, New Jersey, Spojené státy, 07054
      • Voorhees, New Jersey, Spojené státy, 08043
    • New Mexico
      • Santa Fe, New Mexico, Spojené státy, 87505
    • New York
      • Brockport, New York, Spojené státy, 14420
      • Canandaigua, New York, Spojené státy, 14424
      • Fresh Meadows, New York, Spojené státy, 11366
      • Geneva, New York, Spojené státy, 14456
      • Greece, New York, Spojené státy, 14626
      • Lake Success, New York, Spojené státy, 11042
      • Mount Kisco, New York, Spojené státy, 10549
      • Rochester, New York, Spojené státy, 14626
      • Stony Brook, New York, Spojené státy, 11794
    • North Carolina
      • Charlotte, North Carolina, Spojené státy, 28203
      • Durham, North Carolina, Spojené státy, 27710
      • Hickory, North Carolina, Spojené státy, 28602
      • Kinston, North Carolina, Spojené státy, 28501
      • Washington, North Carolina, Spojené státy, 27889
    • Ohio
      • Cleveland, Ohio, Spojené státy, 44195
      • Cleveland, Ohio, Spojené státy, 44106
      • Columbus, Ohio, Spojené státy, 43215
      • Columbus, Ohio, Spojené státy, 43219
      • Columbus, Ohio, Spojené státy, 43228
      • Middletown, Ohio, Spojené státy, 45042
      • Newark, Ohio, Spojené státy, 43055
      • Sandusky, Ohio, Spojené státy, 44870
    • Oregon
      • Portland, Oregon, Spojené státy, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19124
      • Philadelphia, Pennsylvania, Spojené státy, 19106
      • Pittsburgh, Pennsylvania, Spojené státy, 15232
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
    • Rhode Island
      • East Providence, Rhode Island, Spojené státy, 02915
    • South Carolina
      • Columbia, South Carolina, Spojené státy, 29210
      • North Charleston, South Carolina, Spojené státy, 29425
    • Tennessee
      • Memphis, Tennessee, Spojené státy, 38120
      • Nashville, Tennessee, Spojené státy, 37203
    • Texas
      • Austin, Texas, Spojené státy, 78731
      • Bryan, Texas, Spojené státy, 77802
      • Cypress, Texas, Spojené státy, 77429
      • Dallas, Texas, Spojené státy, 75230
      • El Paso, Texas, Spojené státy, 79902
      • Houston, Texas, Spojené státy, 77090
      • Shenandoah, Texas, Spojené státy, 77384
      • Temple, Texas, Spojené státy, 76501
    • Virginia
      • Fairfax, Virginia, Spojené státy, 22031
    • Washington
      • Gig Harbor, Washington, Spojené státy, 98332
      • Lakewood, Washington, Spojené státy, 98499
      • Puyallup, Washington, Spojené státy, 98372
      • Tacoma, Washington, Spojené státy, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Spojené státy, 53226
      • Wausau, Wisconsin, Spojené státy, 54401
  • Tchaj-wan
      • Kaohsung, Tchaj-wan, 883
      • Taichung, Tchaj-wan, 404
      • Taichung, Tchaj-wan, 407
      • Taipei, Tchaj-wan, 112
      • Taoyuan, Tchaj-wan, 333
  • Španělsko
      • Barcelona, Španělsko, 08035
      • Córdoba, Španělsko, 14004
      • Lerida, Španělsko, 25198
      • Madrid, Španělsko, 28046
      • Madrid, Španělsko, 28041
      • Santander, Španělsko, 39008
      • Sevilla, Španělsko, 41013
      • Valencia, Španělsko, 46009
      • Zaragoza, Španělsko, 50009
  • Švédsko
      • Eskilstuna, Švédsko, 63188
      • Gaelve, Švédsko, 80187
      • Goteborg, Švédsko, 40036
  • Švýcarsko
      • Luzern, Švýcarsko, 6004
      • St. Gallen, Švýcarsko, 9007

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Lék: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Ostatní jména:
  • RO5304020
  • T-DM1
  • Trastuzumab-MCC-DM1
Aktivní komparátor: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Lék: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Ostatní jména:
  • Tykerb
  • Tyverb
Lék: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Ostatní jména:
  • Xeloda

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Časové okno: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Časové okno: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Časové okno: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Časové okno: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Časové okno: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Časové okno: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Participants With PD or Death as Assessed by the Investigator
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Časové okno: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Hoffmann-La Roche

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. února 2009

Primární dokončení (Aktuální)

1. července 2012

Dokončení studie (Aktuální)

1. září 2015

Termíny zápisu do studia

První předloženo

22. ledna 2009

První předloženo, které splnilo kritéria kontroly kvality

22. ledna 2009

První zveřejněno (Odhad)

26. ledna 2009

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Odhad)

31. října 2016

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. září 2016

Naposledy ověřeno

1. září 2016

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • BO21977
  • TDM4370g (Jiný identifikátor: Genentech)

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Rakovina prsu

Klinické studie na Trastuzumab emtansine

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Costa Rica

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit